Cipla has received final US FDA approval for its Nilotinib Capsules (50 mg, 150 mg, 200 mg) for the treatment of Philadelphia ...

Nilotinib is an FDA approved drug used for the treatment of Philadelphia Chromosome Positive CML, which is a cancer of blood ...

The company reported a 48% year-on-year (y-o-y) jump in its consolidated net profit to ₹1,571 crore in October-December, while its total revenue from operations rose 8% to ₹7,073 crore. Analysts ...

Stocks like CIE Automotive India, Sanofi Consumer Healthcare, Delta Corp, Mahindra and Mahindra, Grindwell Norton, Keystone ...

India's Cipla beats Q3 profit view as strong domestic ... joint venture with Nestle India and Nicotinell acquisition, the company said on Tuesday. India's Dr Reddy's Q2 profit drops on acquisition ...

That more than made up for a 1% drop in sales in North America, Cipla's second-biggest market, and helped the company's total revenue climb 7.1% to 70.73 billion rupees, surpassing market ...

Cipla share price will remain in focus after the United States Food and Drug Administration (USFDA) has classified the ...

So, within the generic companies, from the US point of view, Cipla delivered a very good set of results supported by the niche launches. And if you see, the commentary has also been very positive.

Mumbai: Cipla Limited has announced that the Company has completed an investment of approx. ZAR 900 million in Cipla Medpro ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Mahindra Lifespace Developers Ltd., Bank of India, Rail Vikas Nigam Ltd., Container Corp. and Cipla Ltd. are some of the ...

The USFDA has conducted routine cGMP inspection at the facility in the period between November 7 through November 13, 2024.